Phosphoproteomics Analysis in Cancer Research
- TiO₂- or Fe-NTA-based enrichment for Ser/Thr phosphopeptides
- Immunoaffinity enrichment targeting Tyr phosphopeptides
- Sequential enrichment strategies (SIMAC) to separate multiphosphorylated peptides
- Activation of DNA repair pathways
- Induction of EMT (epithelial-mesenchymal transition)
- Suppression of cell-cycle checkpoints
- Target discovery: prioritizing selective kinase inhibitors based on phosphorylation profiles.
- Mechanistic studies of drug resistance: revealing compensatory activation of signaling pathways following targeted therapies.
- Biomarker development: establishing phosphorylation sites as prognostic and/or diagnostic biomarkers.
- Personalized treatment design: informing drug recommendations based on phosphoproteomic maps derived from patient tumor tissues.
Protein phosphorylation is among the most prevalent post-translational modifications and plays essential roles in regulating the cell cycle, apoptosis, metabolic reprogramming, and tumor metastasis. Systematic interrogation of the phosphoproteome enables researchers to capture a global view of dysregulated kinase activity and signaling-network rewiring in cancer cells. Phosphorylation occurs primarily on serine (Ser), threonine (Thr), and tyrosine (Tyr) residues, with kinases catalyzing phosphate addition and phosphatases mediating dephosphorylation. This highly dynamic modification can respond rapidly to both intracellular and extracellular cues. Notably, many oncogenic driver genes in cancer encode kinase proteins. Accordingly, phosphoproteomics is widely applied to infer kinase activity states, construct signaling pathway network maps, and identify potential therapeutic targets as well as mechanisms underlying treatment resistance.
Experimental Workflow: End-to-End Optimization From Samples to Data
High-quality phosphoproteomics data depend on rigorous control of multiple experimental steps.
1. Sample Preparation: Protecting and Preserving Phosphorylation
Phosphorylation can be readily removed by phosphatases during cell lysis and proteolytic digestion. Therefore, potent phosphatase inhibitors should be included in lysis buffers, and samples should be processed rapidly to preserve native phosphorylation states. For tissue specimens, thorough homogenization and lipid-removal (defatting) procedures are often required.
2. Enrichment Strategies: Improving the Detection of Low-Abundance Phosphopeptides
Because phosphopeptides represent only a small fraction of the total proteome, enrichment is indispensable. Commonly used approaches include:
3. LC-MS/MS Analysis: Instrument Selection Shapes Analytical Depth
High-resolution MS platforms such as Orbitrap Exploris and Fusion Lumos instruments offer broad dynamic range and improved quantitative accuracy. When combined with DIA (data-independent acquisition), workflows can further enhance coverage and quantitative consistency, thereby improving the likelihood of detecting low-abundance phosphopeptides.
Data Analysis and Biological Interpretation: Extracting the Underlying Regulatory Logic
The ultimate value of phosphoproteomics lies in enabling a deep understanding of signaling pathway alterations. Downstream analyses can support:
1. Kinase-Substrate Prediction
Tools such as Kinase-Substrate Enrichment Analysis (KSEA) can be used to infer changes in upstream kinase activities, facilitating the nomination of candidate kinases as potential drug targets.
2. Signaling Pathway Enrichment Analysis
By leveraging resources such as Reactome, KEGG, and PhosphoSitePlus, phosphoproteins can be mapped to pathways to identify cancer-associated signaling patterns, including:
3. Integrated Transcriptomics/Proteomics/Metabolomics Analysis
Multi-omics integration helps determine whether phosphorylation changes translate into functional phenotypes. For example, AKT activation can promote phosphorylation of downstream metabolic enzymes, thereby contributing to increased glycolytic flux in tumors.
Application Scenarios: From Basic Research to Clinical Translation
Applications of phosphoproteomics in cancer research are increasingly extending from foundational studies to clinical translation:
Cancer is fundamentally characterized by extensive dysregulation of cellular signaling, and phosphoproteomics provides a powerful framework for understanding and ultimately intervening in these aberrant networks. Through high-throughput, high-sensitivity phosphoproteomic profiling, researchers can build dynamic, systems-level views of cancer signaling pathways, providing a robust data foundation for targeted therapy and precision medicine. MtoZ Biolabs is committed to integrating state-of-the-art mass spectrometry platforms with professional research services to support cancer research and advance the life sciences toward greater precision.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
